Oppenheimer Reiterates Buy Rating on Eupraxia Pharmaceuticals
Oppenheimer maintains its buy rating for Eupraxia Pharmaceuticals, setting a price target of $17, a 157.97% upside from the current price.
Key Points
- Oppenheimer reiterated its buy rating for Eupraxia Pharmaceuticals on June 26, 2026, with a price target of $17.
- Oppenheimer's $17 price target implies 157.97% upside from Eupraxia Pharmaceuticals Inc.'s ($EPRX) current $6.59 share price.
- Shares of EPRX traded near $6.41 on Saturday, with a market cap of $431.2 million and a beta of 1.477.
- Analysts from Oppenheimer, Stifel, and HC Wainwright & Co. have all set buy ratings with targets ranging from $11 to $25.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Oppenheimer reiterated its buy rating on Eupraxia Pharmaceuticals Inc. (NasdaqCM: EPRX) on June 26, 2026. The firm set a price target of $17, maintaining a positive outlook on the stock. Eupraxia shares were trading around $6.41 on Saturday.
Oppenheimer vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Eupraxia Pharmaceuticals
Several institutional investors have shown interest in Eupraxia Pharmaceuticals. Affinity Asset Advisors, LLC increased its holdings significantly by 1,289,005 shares, now owning 1,589,005 shares valued at approximately $11.5 million. Meanwhile, Ikarian Capital, LLC also boosted its stake by 604,741 shares, bringing its total to 1,214,741 shares worth about $8.8 million. On the other hand, Beutel, Goodman & Co Ltd. trimmed its position by 42,908 shares, now holding 3,666,465 shares valued at $26.4 million.
Eupraxia Pharmaceuticals Inc. Stock Down 1.3%
Shares of Eupraxia Pharmaceuticals Inc. traded near $6.41 on Saturday. The company has a market capitalization of approximately $431.2 million. It operates with a beta of 1.477, indicating a higher volatility compared to the market. The stock's 52-week range is between $4.67 and $9.32, and it has a 50-day moving average of $6.87 and a 200-day moving average of $6.92. The company is not currently profitable, as reflected by its negative forward P/E ratio of -7.33.
$EPRX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Analysts Set New Price Targets
On June 26, 2026, Oppenheimer reiterated its buy rating on Eupraxia Pharmaceuticals with a price target of $17. Earlier, on May 21, 2026, Stifel initiated coverage with a buy rating and a $25 target. HC Wainwright & Co. maintained its buy rating on March 17, 2026, with a target of $11. The consensus among nine analysts is a strong buy, with a mean price target of $16.28.
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company based in Victoria, Canada. It focuses on developing products for therapeutic areas with unmet medical needs. The company uses its proprietary Diffusphere technology to optimize drug delivery. Its leading product, EP-104IAR, is in Phase III trials for knee osteoarthritis, while EP-104GI is in Phase II for eosinophilic esophagitis. The company is led by CEO Dr. James A. Helliwell and employs around 49 people.
Bottom Line
Eupraxia Pharmaceuticals continues to attract attention from analysts and institutional investors, with Oppenheimer reiterating a buy rating and setting a $17 price target. The stock's recent trading activity and institutional moves suggest ongoing interest in its development pipeline. As a clinical-stage company, its future performance will largely depend on the outcomes of its trials and regulatory milestones.
Get Eupraxia Pharmaceuticals Inc. alerts
New 13F filings, insider trades, and analyst moves on $EPRX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.